Literature DB >> 6721286

Branhamella catarrhalis pneumonia and immunoglobulin abnormalities: a new association.

L A Diamond, B Lorber.   

Abstract

A case of Branhamella catarrhalis pneumonia in a patient with multiple myeloma is reported. With the inclusion of this case, 5 of 17 (29.4%) reported cases of Branhamella pneumonia or empyema have occurred in patients with underlying diseases associated with immunoglobulin abnormalities. This strong clinical association suggests that qualitatively and quantitatively normal immunoglobulins are important host defense mechanisms in preventing infection with this pathogen. The sputum Gram stain demonstrating kidney-shaped gram-negative diplococci may be an early clue to the diagnosis, as well as an initial guide to empiric therapy, and may help the laboratory isolate and identify this pathogen, which, because of its morphologic resemblance to Neisseria, is frequently reported as "normal flora".

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721286     DOI: 10.1164/arrd.1984.129.5.876

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  15 in total

1.  Labile type-specific antigen of Moraxella catarrhalis.

Authors:  S J Norkus; J W Vennes
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

2.  Increase in bronchopulmonary infection due to branhamella catarrhalis.

Authors:  D T McLeod; F Ahmad; S Capewell; M J Croughan; M A Calder; A Seaton
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-26

3.  Lack of immunoglobulin A1 protease production by Branhamella catarrhalis.

Authors:  D T McLeod; M J Croughan; F Ahmad; R P Brettle; M A Calder
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

4.  In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis.

Authors:  S Alvarez; M Jones; S Holtsclaw-Berk; J Guarderas; S L Berk
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

5.  Phenotypic characteristics of Branhamella catarrhalis strains.

Authors:  J L Soto-Hernandez; S Holtsclaw-Berk; L M Harvill; S L Berk
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

Review 6.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

7.  Bronchopulmonary infection due to B. catarrhalis. Clinical features and therapeutic response.

Authors:  D T McLeod; F Ahmad; M J Croughan; M A Calder
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Human immune response against outer membrane proteins of Moraxella (Branhamella) catarrhalis determined by immunoblotting and enzyme immunoassay.

Authors:  M E Helminen; R Beach; I Maciver; G Jarosik; E J Hansen; M Leinonen
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

9.  Amoxicillin-clavulanic acid in the treatment of lower respiratory tract infections caused by beta-lactamase-positive Haemophilus influenzae and Branhamella catarrhalis.

Authors:  R J Wallace; L C Steele; D L Brooks; J I Luman; R W Wilson; J W McLarty
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

10.  Maternal antibodies and acquired serological response to Moraxella catarrhalis in children determined by an enzyme-linked immunosorbent assay.

Authors:  T Ejlertsen; E Thisted; P A Ostergaard; J Renneberg
Journal:  Clin Diagn Lab Immunol       Date:  1994-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.